Interim report for the three months ended March 31, 2008

 | Source: Affitech A/S Affitech A/S 

Summary: For the first three months of 2008 the Pharmexa Group generated
revenues and other operating income of DKK 6,926 thousand and a net loss of DKK
35,538 thousand. Research and development costs totalled DKK 37,471 thousand.
The Pharmexa Group retains its forecast for the full year.

Attachments

pharmexa press release 2008-14-uk.pdf
GlobeNewswire